Kura Oncology Inc. (KURA)
Kura Oncology, Inc. - Special Call
Kura Oncology, Inc. - Special Call Company Participants Troy Wilson - Chairman, CEO & President Francis Burrows - Chief Scientific Officer Mollie Leoni - Chief Medical Officer Conference Call Participants Jonathan Chang - Leerink Partners LLC, Research Division Jiale Song - Jefferies LLC, Research Division Yue-Wen Zhu - LifeSci Capital, LLC, Research Division Philip Nadeau - TD Cowen, Research Division Peter Lawson - Barclays Bank PLC, Research Division Salim Syed - Mizuho Securities USA LLC, Research Division Presentation Operator Thank you for standing by and welcome to Kura Oncology's FT Pre-clinical Program Review: Synergistic Combinations with Targeted Therapies. [Operator Instructions] I would now like to hand the call over to Troy Wilson, CEO.
Kura Oncology, Inc. (KURA) Q2 2025 Earnings Call Transcript
Kura Oncology, Inc. (NASDAQ:KURA ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Brian T. Powl - Chief Commercial Officer Greg Mann - Corporate Participant Mollie Leoni - Chief Medical Officer Thomas Doyle - Senior Vice President of Finance & Accounting Troy Edward Wilson - Chairman, CEO & President Conference Call Participants Ellen Horste - TD Cowen, Research Division Eric Tatenda Musonza - UBS Investment Bank, Research Division Jason Eron Zemansky - BofA Securities, Research Division Li Wang Watsek - Cantor Fitzgerald & Co., Research Division Peter Green - Unidentified Company Peter Richard Lawson - Barclays Bank PLC, Research Division Roger Song - Jefferies LLC, Research Division Suranjit Mukherjee - BTIG, LLC, Research Division Wei Ji Chang - Leerink Partners LLC, Research Division Operator Hello, and welcome, everyone, joining today's Second Quarter 2025 Kura Oncology, Inc. Financial Results Conference Call.
Kura Oncology (KURA) Reports Q2 Loss, Lags Revenue Estimates
Kura Oncology (KURA) came out with a quarterly loss of $0.75 per share versus the Zacks Consensus Estimate of $0.15. This compares to a loss of $0.59 per share a year ago.
Is the Options Market Predicting a Spike in Kura Oncology Stock?
Investors need to pay close attention to KURA stock based on the movements in the options market lately.
KURA Stock Rises More Than 15% This Past Week: Here's Why
Kura Oncology shares rise this week after the FDA accepts its NDA for ziftomenib, a potential first-in-class treatment for NPM1-mutant AML.
Kura Oncology, Inc. (KURA) Q1 2025 Earnings Call Transcript
Kura Oncology, Inc. (NASDAQ:KURA ) Q1 2025 Earnings Conference Call May 1, 2025 4:30 PM ET Company Participants Troy Wilson – President and Chief Executive Officer Mollie Leoni – Chief Medical Officer Tom Doyle – Senior Vice President of Finance and Accounting Brian Powl – Chief Commercial Officer Conference Call Participants Jonathan Chang – Leerink Partners Salim Syed – Mizuho Cameron Bozdog – Bank of America Charles Zhu – LifeSci Capital Ellen Horste – TD Cowen Peter Lawson – Barclays David Dai – UBS Jeet Mukherjee – BTIG George Farmer – Scotiabank Roger Song – Jefferies Operator Good day everyone and welcome to today's First Quarter 2025 Kura Oncology Financial Results Conference Call. At this time, all participants are in a listen-only mode.
Kura Oncology (KURA) Reports Q1 Loss, Lags Revenue Estimates
Kura Oncology (KURA) came out with a quarterly loss of $0.66 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to loss of $0.59 per share a year ago.
Kura Oncology: The Market Sees A Tough Road Ahead, And I Think There's An Opportunity
Kura Oncology's ziftomenib shows promise in AML treatment, with key data readouts expected in 2025, but faces competition from Syndax's revumenib. Kura's strong cash position supports operations through 2027, bolstered by a lucrative deal with Kyowa Kirin, despite a 50/50 profit share. Market sentiment is low due to second-mover disadvantage and delayed catalysts, but current valuations present a potential buying opportunity.
Kura Oncology, Inc. (KURA) Q4 2024 Earnings Call Transcript
Kura Oncology, Inc. (NASDAQ:KURA ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Patti Bank - IR Troy Wilson - President and CEO Mollie Leoni - CMO Tom Doyle - SVP of Finance and Accounting Brian Powl - CCO Conference Call Participants Li Watsek - Cantor Fitzgerald Yen-Der Li - Leerink Partners Jason Zemansky - Bank of America Peter Lawson - Barclays Dara Azar - Stifel Charles Zhu - LifeSci Capital David Dai - UBS Justin Zelin - BTIG George Farmer - Scotiabank Operator Good day, everyone, and welcome to today's Q4 2024 Kura Oncology, Inc. Financial Results Conference Call. At this time, all participants are in a listen-only mode.
Kura Oncology (KURA) Reports Q4 Loss, Lags Revenue Estimates
Kura Oncology (KURA) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.63. This compares to loss of $0.55 per share a year ago.
Kura Oncology Cancer Study Hits Primary Goal, Lays Out Plans For Phase 3 Studies
Kura Oncology, Inc. KURA and Kyowa Kirin Co., Ltd released topline results from a Phase 2 registration-directed trial of ziftomenib for relapsed/refractory (R/R) NPM1-mutant (NPM1-m) acute myeloid leukemia (AML).
Kura Oncology Presents Deep Value At Today's Prices (Rating Upgrade)
Kura Oncology, Inc.'s collaboration with Kyowa Kirin brings $330M upfront and a potential $1.2B in milestone payments, enhancing long-term shareholder value despite initial market disappointment. Ziftomenib, Kura's lead candidate, shows promising results in AML treatment, with a 35% complete remission rate, and could address up to 50% of AML patients. The stock is upgraded to Strong Buy due to its deep value, strong pipeline performance, and potential for substantial upside if FDA approval and commercialization go according to plan.
